Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests (CT-MPACT)
Coronary CT angiography (CCTA) offers great promise as a risk stratification tool in patients with suspected CAD. It has been demonstrated in a multitude of accuracy studies to have a negative predictive value averaging over 95%. This leads to the hypothesis that a negative CCTA may preclude the need for invasive testing. The purpose of this randomized controlled study is to prospectively evaluate the role of CCTA on the management of patients with inconclusive or indeterminate stress test results.CCTA is able to provide not only information on presence and extent of coronary artery calcification, but detailed coronary anatomy as well.
SPECIFIC AIM # 1: To evaluate the diagnostic and prognostic performance of CCTA in patients with equivocal / intermediate stress test results as compared to conventional invasive coronary angiography.
SPECIFIC AIM # 2: To evaluate the utility of CCTA in prediction of major adverse cardiac events (MACE) compared to invasive coronary angiography at 30 days, 1 year, 3 years and 5 years.
調査の概要
状態
条件
詳細な説明
Outpatients scheduled to undergo cardiac catheterization and coronary angiography for the specific indication of inconclusive or indeterminate stress tests will be considered for this study. Patients will be initially screened by their cardiologist for the presence of inclusion/exclusion criteria, as well as pre-test and post-test likelihood of CAD.16, 17 All patients must have undergone a stress (exercise or pharmacologic) test within the past 3 months.
After consent, patients will be randomized 1:1 to undergo CCTA or cardiac catheterization. The decision whether or not to proceed with subsequent invasive cardiac catheterization (CCTA arm) or revascularization (catheterization arm) will be made by the patient's primary and interventional cardiologists respectively.
Inclusion:
- Chest pain or other symptoms suggestive of coronary artery disease.
- Pharmacologic/exercise stress test with SPECT (nuclear myocardial-heart perfusion imaging) within the past 3 months.
- "Discordant or conflicting findings" clinical and stress results as outlined above.
- Scheduled to undergo cardiac catheterization.
- Able to provide informed consent.
- Age equal to or greater than 18 years.
Exclusion:
- Presence of pre-existing heart disease (prior heart attack, prior angiographic evidence of significant heart disease, prior heart surgery) or cardiomyopathy (ejection fraction less than or equal to 45%)
- History of high blood pressure with severe left ventricular hypertrophy (thicken heart muscle), history of cor pulmonale (right heart chamber failure due to elevated blood pressures in the arteries delivering blood to the lungs).
- Kidney insufficiency (creatinine greater than or equal to 1.6) or kidney failure requiring dialysis.
- Inability or refusal to provide informed consent.
- Psychological unsuitability or extreme claustrophobia (fear of closed in spaces).
- Pregnancy or unknown pregnancy status.
- Age less than 18 years.
- Patients with known allergy to iodinated contrast, unable to tolerate pre-medication.
- Inability to tolerate beta-blockers (medication to slow the heart rate), including those with COPD or asthma requiring maintenance inhaled bronchodilators or steroids, complete heart block, second-degree atrioventricular block.
- Computed tomography imaging, or contrast administration, within the past 48 hours.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Michigan
-
Royal Oak、Michigan、アメリカ、48073
- William Beaumont Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Chest pain or other symptoms suggestive of coronary artery disease.
- Pharmacologic/exercise stress test with SPECT within the past 3 months.
- "Discordant" clinical and stress results as outlined above.
- Scheduled to undergo cardiac catheterization.
- Able to provide informed consent.
- Age equal to or greater than 18 years.
Exclusion Criteria:
- Presence of pre-existing CAD (prior myocardial infarction, prior angiographic evidence of significant coronary artery disease, prior coronary bypass surgery) or cardiomyopathy (ejection fraction < 45%)
- History of hypertension with severe left ventricular hypertrophy, history of cor pulmonale.
- Renal insufficiency (creatinine ≥1.6) or renal failure requiring dialysis.
- Inability or refusal to provide informed consent.
- Psychological unsuitability or extreme claustrophobia.
- Pregnancy or unknown pregnancy status.
- Age less than 18 years.
- Patients with known allergy to iodinated contrast, unable to tolerate pre-medication.
- Inability to tolerate beta-blockers, including those with COPD or asthma requiring maintenance inhaled bronchodilators or steroids, complete heart block, second-degree atrioventricular block.
- Computed tomography imaging, or contrast administration, within the past 48 hours.
研究計画
研究はどのように設計されていますか?
デザインの詳細
協力者と研究者
捜査官
- 主任研究者:Kavitha Chinnaiyan, MD、William Beaumont Hospitals
- スタディディレクター:Gilbert Raff, MD、William Beaumont Hospitals
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
冠動脈疾患の臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ